Table 1 Demographic and characteristics according to the BDNF genotype.
BDNF Val/Val (n = 30) | BDNF Val/Met (n = 12) | p-value | |
|---|---|---|---|
Body mass index (kg/m2) | 30.0 (5.05) | 27.40 (5.745) | 0.157 |
Age (years) | 49.733 (8.28) | 44.667 (8.049) | 0.079 |
Education (years) | 11.066 (4.017) | 15.727 (3.289) | 0.001 |
Employed (yes) | 16 (53.3%) | 11 (91.7%) | |
Smoking (yes) | 9 (30%) | 2 (16.7%) | |
Alcohol use (yes) | 13 (43.3%) | 5 (41.7%) | |
Opioid analgesic medication in use (yes) | 8 (26.7%) | 0 (0%) | |
Non-opioid analgesic medication in use (yes) | 30 (100%) | 10 (83.3%) | |
Chronic disease (yes) | 15 (50%) | 8 (66.6%) | |
Hypertension (yes) | 9 (30%) | 2 (16.7%) | |
Type 2 Diabetes Mellitus (yes) | 2 (6.7%) | 0 (0%) | |
Asthma (yes) | 2 (6.7%) | 4 (33.3%) | |
History of major depression disorder (yes) | 23 (76.7%) | 8 (66.7%) | |
Use psychiatric drugs (yes)** | 17 (56.7%) | 11 (91.7%) | |
Selective serotonin reuptake inhibitor in use (yes) | 7 (23.3%) | 3 (25%) | |
Tricyclic antidepressant (yes/no) | 5 (16.7%) | 1 (8.3%) | |
Benzodiazepine | 6 (20%) | 2 (16.7%) | |
Visual Analogue Scale (10 cm) | 8.178 (1.498) | 8.209 (1.048) | 0.948 |
Brazilian Pain Catastrophizing Scale | 35.267 (10.935) | 32.167 (12.276) | 0.427 |
Central Sensitization Inventory | 64.133 (17.254) | 60.833 (17.903) | 0.583 |
Fibromyalgia Impact Questionnaire | 71.975 (15.031) | 59.586 (19.547) | 0.039 |
Pittsburgh Sleep Quality Index | 12.933 (3.40) | 12.917 (4.07) | 0.99 |
ACR score | 23.87 (3.34) | 21.92 (4.19) | 0.12 |
(i) Widespread pain index | 14.567 (2.622) | 12.333 (3.312) | 0.026 |
(ii) Generalized pain: pain in 4/5 regions | 10.267 (1.721) | 9.583 (1.73) | 0.253 |
BDNF serum (ng/ml) | 37.679 (25.089) | 27.087 (11.576) | 0.170 |
